United States

Abstract Title:
Exploring the Link Between Smoking and Short-Term Mortality in Hospitalized COVID-19 Patients: Insights from Population Data
Background
Smoking cigarettes represents a prevalent form of tobacco consumption, with cigarette smoke containing harmful substances like nicotine, tar, and various carcinogens, which contribute to a spectrum of health issues. This study extends the discussion of smoking in the context of the COVID-19 pandemic, where data suggests that non-smokers hospitalized with the COVID-19 virus are more vulnerable to complications.
Methods
To investigate the relationship between smoking history and short-term mortality among COVID-19 patients, publicly accessible deidentified statewide hospitalization records of individuals aged ≥18 from Q2 2020 to Q1 2022 in Texas were utilized. Identification of smokers was performed using ICD-10-CM codes F17200, Z8789, and U071. Three models were employed to assess this link: multilevel logistic regression with propensity adjustment, supported by alternative analyses including propensity score matching and multivariable logistic regression.
Results
Nicotine administration has been observed to increase nAChR7 expression and inhibit pro-inflammatory cytokines like TNF-α, IL-1, and IL-6, while stimulating anti-inflammatory cytokines such as IL-10. Moreover, nicotine&#39;s potential dual effect on ACE2 receptors—increasing expression while reducing available binding sites for the COVID-19 virus—has been highlighted. Additionally, nicotine has been shown to inhibit NF-κB, a critical transcription factor in the activation of inflammation in various immune cells, and as an agonist of α7nAChRs, it can reduce cytokine storm mediators such as HMGB1. Notably, smoking has been associated with reduced furin (PCSK3) levels.
Conclusion
In conclusion, nicotine, widely consumed as tobacco smoking and recognized as an addictive substance, may harbor therapeutic potential that necessitates further exploration. Analogous pharmacological agents with high addictive potential are presently utilized for therapeutic purposes with appropriate pharmaceutical protocols. Further research into nicotine&#39;s standard processing, therapeutic index, dosing, and other aspects is imperative. Despite the inherent limitations of retrospective studies, nicotine has demonstrated mortality benefits, underscoring the importance of further investigation through prospective studies.

AMA Research Challenge 2024 

Exploring the Paradoxical Relationship Between Smoking and Short-Term Mortality in Hospitalized COVID-19 Patients: Insights from a Population-Based Cohort Study

Colleagues and Friends:

I am very happy to welcome you to the 14th annual Canadian Neuroscience Meeting, and to the first virtual edition of our meeting. I want to highlight the important work the CAN meeting chair, **Roger Thompson** and co-chair, **Alyson Fournier**, did to put together the great program we are offering this year. Moving to a virtual format required a complete re-design of the program, and both Roger and Alyson did a splendid job in providing us with an appealing and well adapted program for our first virtual event. I wish to thank them for this very important effort.

Highlights of this year’s scientific meeting include invited speakers **Michael Hausser, Franck Polleux, Gwyneth Card, Magdalena Götz**and Brain Prize winner **Huda Zoghbi**. Plenary and parallel symposia, proposed by our members complete our diverse [scientific program.](https://can-acn.org/meeting-2021/program-2021/)

The 2021 Advocacy session, chaired and organized by CAN advocacy committee chair **Karun Singh**, will feature a special lecture and question period with Member of Parliament and past Science Minister **Kirsty Duncan**. This will be followed by a short overview of CAN’s advocacy activities over the last year. We invite you to participate in this session for insight from Dr. Duncan on the workings of Parliament Hill, and to learn more about what CAN has been doing to promote neuroscience research in Canada.

We are also excited to host **Lisa Willis** in the Equity Diversity and Inclusion session, organized by EDI committee chair **Jibran Khokhar**.

A special highlight of our meeting will be the lectures by award-winning young neuroscientists. We are please to host the CAN 2020 Young Investigator Award winner **Mihaela Iordanova**, and CAN 2021 Young Investigator Award winners **Aaron Phillips** and **Tabrez Siddiqui**. Highlights will also include presentation by the top three winners of the CAN-CIHR-INMHA Brain Star Award winners, **Claire Gizowski, Nuria Daviu Abant** and **Lukas Tamayo-Orrego**.

Independently organized satellite symposia complement and complete this exciting program, check them out here: https://can-acn.org/meeting-2021/2021-satellite-symposia/

Some of the most engaging sessions are always the poster sessions featuring the work of our trainees, so make sure to log in to Gather Town during the poster sessions to chat with the presenters.
We hope you enjoy this program, and look forward to welcoming you, virtually.

Shernaz Bamji

President of the Canadian Association for Neuroscience

![](https://assets.underline.io/uploads/markdown_image/1/image/b9aea25343a87d5aac3b9367dc780974.jpg)



Please head to https://can-acn.org/meeting-2021/registration-2021/ to register. 

CAN-ACN 2021

14th Canadian Neuroscience Meeting from August 23rd-25th

Abstract Title:
Exploring the Link Between Smoking and Short-Term Mortality in Hospitalized COVID-19 Patients: Insights from Population Data
Background
Smoking cigarettes represents a prevalent form of tobacco consumption, with cigarette smoke containing harmful substances like nicotine, tar, and various carcinogens, which contribute to a spectrum of health issues. This study extends the discussion of smoking in the context of the COVID-19 pandemic, where data suggests that non-smokers hospitalized with the COVID-19 virus are more vulnerable to complications.
Methods
To investigate the relationship between smoking history and short-term mortality among COVID-19 patients, publicly accessible deidentified statewide hospitalization records of individuals aged ≥18 from Q2 2020 to Q1 2022 in Texas were utilized. Identification of smokers was performed using ICD-10-CM codes F17200, Z8789, and U071. Three models were employed to assess this link: multilevel logistic regression with propensity adjustment, supported by alternative analyses including propensity score matching and multivariable logistic regression.
Results
Nicotine administration has been observed to increase nAChR7 expression and inhibit pro-inflammatory cytokines like TNF-α, IL-1, and IL-6, while stimulating anti-inflammatory cytokines such as IL-10. Moreover, nicotine's potential dual effect on ACE2 receptors—increasing expression while reducing available binding sites for the COVID-19 virus—has been highlighted. Additionally, nicotine has been shown to inhibit NF-κB, a critical transcription factor in the activation of inflammation in various immune cells, and as an agonist of α7nAChRs, it can reduce cytokine storm mediators such as HMGB1. Notably, smoking has been associated with reduced furin (PCSK3) levels.
Conclusion
In conclusion, nicotine, widely consumed as tobacco smoking and recognized as an addictive substance, may harbor therapeutic potential that necessitates further exploration. Analogous pharmacological agents with high addictive potential are presently utilized for therapeutic purposes with appropriate pharmaceutical protocols. Further research into nicotine's standard processing, therapeutic index, dosing, and other aspects is imperative. Despite the inherent limitations of retrospective studies, nicotine has demonstrated mortality benefits, underscoring the importance of further investigation through prospective studies.

poster

Welcome to the **largest national, multi-specialty research** event featuring research from more than 750 medical students, residents, fellows, and international medical graduates.

Use the buttons below or navigation menu to access the event.
 

[![](https://assets.underline.io/markdown_image/1/image/20e1e77aa954efeac7a15d84c85eb383.jpg)](https://underline.io/events/468/sessions?searchGroup=all)
 
[![](https://assets.underline.io/markdown_image/1/image/068522d81aca0b68a369787c7dfccd1b.jpg)](https://underline.io/events/468/posters?searchGroup=all)
 
[![](https://assets.underline.io/markdown_image/1/image/d3971ece79d5e5575b178bdc2c8bbfae.jpg)](https://underline.io/events/468/help-desk)
 

#### Event Details

The 2024 American Medical Association Research Challenge includes a poster symposium hall and a semifinals hall with the top scored research. **Log in at any time throughout the event to:**

* **View posters and presentations** on a variety of topics and specialties
* **Score posters in the semifinals** to help decide the top five finalists (AMA member exclusive opportunity)
* **Connect with participants** and provide feedback to help advance their research

At the conclusion of this event, the AMA will announce the top five finalists who will advance to the AMA Research Challenge finals, present their research to an elite panel of judges, and compete to win a $10,000 grand prize presented by Laurel Road. 

### Grand Prize Sponsor

AMA would like to thank Laurel Road for sponsoring a $10,000 grand prize for the winner of the AMA Research Challenge. Laurel Road is not involved in winner selection process. The winner will be announced on February 20, 2025 during the AMA Research Challenge finals. Payment of the grand prize will be directly from Laurel Road. See the AMA Research Challenge Official Rules for terms and conditions.

[![](https://assets.underline.io/uploads/markdown_image/1/image/611e331d4a0eba0920f240cfc04b4d77.png)](https://www.laurelroad.com/)

You need to log in with the email address you registered with. Access credentials have been sent to your email. 

Please be sure to check your spam and other email folders if you do not see an email confirmation right away.

Please log in to explore this event.

**There is no registration fee for this event! **

If you have used the AMA Research Challenge platform previously, please click the ‘Log-in’ button below. If you do not remember your password, please click “forgot password” and follow prompts to reset your password. After resetting your password, please refresh your webpage to access the platform.

Register to explore research in a variety of topics. AMA members get exclusive access to score posters in the semifinals. 

**Please use this link [here](https://www.ama-assn.org/member-benefits/events/ama-research-challenge) to register for free.**

Registration Is Required

Join the AMA Research Challenge poster symposium and semifinals to explore top research posters and score posters in the semifinals (an AMA member exclusive opportunity).

Background:

Vaccines are a crucial tool in combating infectious diseases, yet not all vaccines are equally effective for every individual. Variations in vaccine response can be influenced by demographic factors, including age, race, gender, and ethnicity, which are sometimes overlooked in different studies. With the advancements in Artificial Intelligence (AI) and Machine Learning (ML), there is now an opportunity to predict vaccine responses more accurately. While most current models use genetic data, our study focuses on cytokine data—small proteins that affect cell interactions. Cytokine profiling measures these proteins to better understand the immune response. We initiated our investigation with two primary influenza vaccines as a pilot: the Live Attenuated Influenza Vaccine (LAIV) and the Trivalent Influenza Vaccine (TIV). This study marks the first-ever use of ML models to predict vaccine response using cytokine profiling in combination with demographic data, aiming to develop more inclusive models in healthcare.

Methods:

We analyzed cytokine profiles from over 300 participants across six influenza studies using the ImmPort database. Data were collected on days 0 (pre-vaccination), 7, and 28. Statistical analyses, including t-tests and ANOVAs, identified cytokine differences by demographics. Participants were classified as responders or non-responders using Hemagglutination Inhibition Assay (HAI) data. ML models were created using pre-vaccination cytokine profiles and demographic data to predict responses to the LAIV and the TIV.
Results

Cytokine profiles significantly differed (P < 0.05) by demographics, with significant differences found in 45/55 cytokines measured. Cytokines when compared by race had the most significant differences, especially between African American and White participants, followed by age, gender, and ethnicity. For TIV, the K-Nearest Neighbors model was the most accurate for predicting responders, with accuracies of 80%, 67%, and 74% for the two A strains and one B strain. Logistic regression was most successful for LAIV with an accuracy of about 80% per strain.

Conclusion:

Our study demonstrates the value of cytokine profiling and the impact of demographics on vaccine response predictions. The integration of cytokine data with demographic factors in ML models can lead to more personalized healthcare and help address health disparities in vaccine efficacy, especially those facing African Americans. Future work will involve validating these models on larger datasets and exploring additional data types, such as flow cytometry, to enhance global health decision-making.

Leveraging Machine Learning Models and Cytokines to Predict Vaccine Response:
Exploring Demographic Influences

Chronic alcohol consumption is known to widely increase inflammation throughout the body giving rise to increased pain hypersensitivity, particularly in patients who have pre-existing conditions such as spinal disorders. Spondylolisthesis is a condition involving vertebral anterior displacement leading to diffuse lower back pain that can be managed via conservative and surgical interventions. Repeat corticosteroid injections can be performed through a procedure known as transforaminal lumbar epidural steroid injection (TFESI) to manage the acute and chronic pain of spondylolisthesis and other spinal disorders. This study aims to compare the frequency of TFESI procedures in alcohol-dependent spondylolisthesis patients to their non-alcohol-dependent counterparts.

We utilized a national database known as TriNetX which compiles de-identified electronic medical records from multiple healthcare organizations over the past 20 years. Patients undergoing TFESI (Current Procedural Terminology [CPT]: 64483) for spondylolisthesis (International Classification of Diseases, Tenth Revision [ICD-10]: M43.1) were categorized based on the presence of alcohol-related disorders (ICD-10: F10). Cohort A was defined as patients with spondylolisthesis who had alcohol-related disorders. Cohort B was defined as patients with spondylolisthesis who did not have alcohol-related disorders. Propensity score matching for age, sex, ethnicity, body mass index (BMI), type 2 diabetes, and opioid-related disorders minimized confounding variables between the two cohorts. We compared major outcomes using measure-of-association analysis, obtaining p-values, risk ratios (RR), and 95% confidence intervals (CI) for each complication.

Among 72,261 patients who underwent TFESI procedures for spondylolisthesis, 767 patients had alcohol-related disorders. After matching, alcohol-related disorders were linked to increased future instances of TFESI procedures (p < 0.0001, RR = 1.28, 95% CI = 1.15-1.43) and lower back pain (p < 0.0001, RR = 1.17, 95% CI = 1.09-1.26).

These findings suggest that alcohol-related disorders are associated with increased utilization of TFESI in patients with spondylolisthesis. These patients may experience more severe pain and poorer functional outcomes, necessitating more frequent interventions. Clinicians should consider the impact of alcohol-related disorders when developing a treatment plan for each individual.

Alcohol-Related Disorders Lead to Increased Transforaminal Lumbar Epidural Steroid Injection (TFESI) Use for Patients with Spondylolisthesis

Dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), holds a significant and expanding role in the medical field. Its approval for various medical conditions, such as alleviating chemotherapy-induced nausea and stimulating appetite in HIV-associated cachexia, is well-documented (Ahmedzai, 2004; Beal, 1995). However, its relevance is now extending into pain management and perioperative care.

Recent research, as indicated by Abrams (2011), suggests that Dronabinol possesses potential as both an antiemetic and analgesic agent, particularly in situations where conventional treatments have limitations. This is particularly significant in the context of the opioid crisis, as Dronabinol offers pain relief without the same associated risks as opioids.

As the medical community seeks alternative solutions to opioid-based pain management, Dronabinol's multifaceted relevance becomes increasingly evident. Supported by a body of clinical trials and research reviews, Dronabinol emerges as a valuable tool in addressing various medical challenges.

The reduction in opioid requirements post-surgery, as seen in the case presented, underscores the potential of Dronabinol in the perioperative setting, and this paper aims to explore its medical, social, economic, and legal aspects comprehensively.

Beyond Opioids: Exploring Dronabinol in Enhanced Recovery After Surgery (ERAS)

Methylene blue is controversially used in the management of refractory vasoplegia and septic shock due to its mechanism of inhibiting guanylate cyclase and decreasing cGMP levels to improve vascular tone. In recent meta-analysis, methylene blue use in septic shock resulted in improvement of hypotension, blood pressure, and cardiac function, while significantly reducing mortality and ICU/hospital stays. Further usage of methylene blue may benefit anaphylactic and drug-induced shock by reducing vasopressor requirements. Administered intravenously, methylene blue peaks at 30 minutes, with effects lasting 48–72 hours, making it a valuable treatment for various shock conditions.


Methylene Blue Use for Refractory Hypotension in Setting of Necrotizing Pancreatitis 

Abstract Title
Postoperative Opioid Use for Regional vs. General Anesthesia in Hip Arthroplasty
Background
Total hip arthroplasty is a commonly performed surgical procedure, especially among elderly patients. Effective anesthesia management significantly influences outcomes and reduces complications. The choice between regional anesthesia (RA) and general anesthesia (GA) remains a subject of ongoing debate. This comprehensive database study aims to compare long-term postoperative opioid usage for pain management between patients who received general anesthesia versus regional anesthesia.
Methods
The study utilized the TriNetX database, comprising deidentified patient information for over 124 million individuals. Subjects with at least two years of follow-up electronic health data were included in the regional (Bupivacaine) and general (Propofol) anesthesia groups. The study focused on patients who underwent total hip arthroplasty (THA) under anesthesia from 2015 to 2021. Propensity score matching was employed in a 1:1 ratio to balance outcome-affecting variables between the two cohorts. Postoperative opioid use was compared across 90 days, 1 year, and 2 years. Statistical analysis, including odds ratios (ORs) and 95% confidence intervals (CIs), was conducted using the TriNetX database.
Results
A total of 253,827 patients underwent THA under anesthesia, with 112,206 under regional anesthesia and 150,930 under general anesthesia. Propensity score matching resulted in 112,205 patients in both the regional and general anesthesia groups. Following matching, statistical analysis revealed no significant differences in opioid use between regional and general anesthesia groups at 90 days [(OR (95% CI), 1.17 (0.96, 1.425)], 1 year [OR (95% CI), 1.123 (0.983, 1.284)], and 2 years [OR (95% CI), 1.105 (0.991, 1.232)].
Conclusion
The findings suggest that regional anesthesia does not provide superior postoperative pain control with reduced opioid consumption compared to general anesthesia. However, regional anesthesia may lead to shorter hospital stays for these patients. Clinicians should consider these results when customizing anesthesia strategies for individual patients, aiming to achieve the most suitable plan based on each patient's specific needs.

Postoperative Opioid Use for Regional vs. General Anesthesia in Hip Arthroplasty

Background: A hemodynamically significant patent ductus arteriosus (HSPDA) is a common concern in the care of premature infants, but its definition remains a challenge and its preferred treatment remains controversial. 

Methods: We sent an electronic survey to the members of the AAP Sections on Neonatal and Perinatal Medicine, Cardiology and Cardiac Surgery and the PediHeartNet online community regarding their diagnosis and treatment of the HSPDA in premature infants.

Results: 382 neonatologists and 124 pediatric cardiologists completed the survey. Formal echocardiographic and clinical scoring systems for PDA were used infrequently (22.1% and 15.5%). Neonatologists and pediatric cardiologists had significantly different (P<0.001) perceptions of the importance in 11 of 14 echocardiographic parameters used to determine a HSPDA. Surgical ligation was less frequently recommended than catheter closure.

Conclusion: This survey reflects the current best practice in the care of HSPDA and suggests an emphasis on imaging based on clinical condition with formal scoring systems used infrequently.. The difference in perceived value of various echocardiographic parameters between neonatologists and cardiologists may contribute to uncertainty in the determination of HSPDA. Despite being a relatively new technology, catheter occlusion of the HSPDA is recommended more frequently than surgical ligation by this cohort.

A Survey Regarding the Care of the Hemodynamically Significant Patent Ductus Arteriosus (HSPDA)

Background
Bicuspid aortic valve (BAV) is the most common congenital heart condition. BAV complications include aortic valve surgery, aortic surgery, infective endocarditis, and aortic dissection. Due to its 10% chance of transmission to offspring and lifetime morbidity burden of >80%, screening of first-degree relatives is recommended for early detection. Several barriers to echocardiographic screening for BAV have been identified, therefore, a cheap and fast “rule-out” BAV tool is appealing. The objective of our study is to create an artificial intelligence (AI)-enabled electrocardiogram (ECG) model to aid the detection of BAV in suspected individuals.
Methods
Between January 1, 1990, and June 30, 2023, 13,066 adults [mean age 58.3±17 years, 46.6% women] with both an ECG and an echocardiographic study within 6 months of each other, were identified from the Mayo Clinic database. Cases were selected as patients with a confirmed BAV diagnosis either by echocardiographic or pathologic report. Controls were selected as patients with an ECG indication of abnormal auscultation, rule out, suspected, or family history of BAV. Patients were excluded if they displayed any of the following criteria: a previous heart surgery or procedure, potential cardiac remodeling conditions(cardiomyopathies, history of chemotherapy or radiation, autoimmune disease, previous known congenital heart disease, heart failure, myxomas, history of endocarditis, rheumatic heart disease, heart transplant and pacemaker). ECGs by patient were randomly shuffled into mutually exclusive training (80%), internal validation (10%), and test (10%) data sets. A convolutional neural network was built using the Keras Framework under Tensorflow backend (Google;Mountain View,CA,USA).
Results
BAV prevalence in the model’s development was 45%. In the test group, the AI-enabled ECG model achieved an area under the curve (AUC) of 0.704 with the following values: sensitivity 65%, specificity 64.8%, accuracy 64.9%, positive predictive value (PPV) 60.1%, and negative predictive value (NPV) 69.4%.
Conclusion
An AI-enabled ECG model has shown modest diagnostic performance in detecting BAV. When assuming a prevalence of 10% (chance of transmission to offspring), the NPV increases to 94.3% with decreased PPV of 17%. This approach could save a major number of echocardiograms for “ruling-out” BAV, but needs external validation.

Artificial Intelligence-Enabled Electrocardiogram Model for Screening of Bicuspid Aortic Valve

Single ventricle surgical palliation with a Glenn surgery universally leads to unintended pulmonary vascular remodeling with pulmonary arteriovenous malformations (PAVMs) and aortopulmonary collaterals (APCs). The pathogenesis of PAVMs and APCs after Glenn is poorly understood, and published literature is limited. Our research team identified increased macrophages in lung biopsies from patients prior chronic Glenn circulation. Most recently we also identified increased lung macrophages and decreased lung lymphocytes in a surgical animal of Glenn circulation. Because lung macrophages and lymphocytes can originate from the bone marrow and circulate in peripheral blood as monocytes and lymphocytes, we hypothesized that peripheral blood samples from patients with chronic Glenn circulation would demonstrate increased monocytes and decreased lymphocytes compared to age-matched controls. We conducted a retrospective cohort study of patients 0-17 years old who underwent cardiac surgery between 1/1/2012 - 1/1/2024. To assess peripheral blood leukocyte counts, we recorded cell counts from pre-operative complete blood counts (CBC) from patients prior to single ventricle palliation (pre-Glenn and pre-Fontan). We also included age-matched control groups (pre-tetralogy of Fallot surgery and pre-atrial septal defect surgery) because normal leukocyte counts are known to change with age. Patient cohorts were identified through an institutional surgical database and CBCs were recorded through manual chart review immediately prior to the date of surgery. We identified a total of 736 pre-surgical CBCs, including 420 single ventricle CBCs (208 [28.3%] pre-Glenn, 212 [28.8%] pre-Fontan) and 316 control CBCs (156 [21.2%] pre-ASD, 160 [21.7%] pre-TOF). There was no difference in years of age at surgery between our age-matched groups (pre-Glenn 0.35 [0.28, 0.45] vs pre-TOF 0.35 [0.21, 0.50]; p>0.99) (pre-Fontan 3.5 [3.0, 4.1] vs pre-ASD 4.3 [3.0, 7.1]; p=0.19). Compared to their respective age-matched control groups, the pre-Fontan group had increased absolute monocytes (p<0.0001), whereas the pre-Glenn group was not different (p=0.57). Surprisingly, both single ventricle groups had decreased absolute lymphocyte counts (both p<0.0001) and increased absolute neutrophil counts (both p=0.01) compared to their respective control groups. In our single institutional study, chronic Glenn circulation is associated with increased monocytes and decreased lymphocytes in peripheral blood compared to an age-matched control group with an isolated ASD. Further investigation is needed to determine whether peripheral blood leukocyte counts may serve as a biomarker to predict clinical outcomes.

Assessment of leukocyte dysregulation in single ventricle congenital
heart disease

Association Between Pulmonary Artery Catheterization (PAC) Mortality, Length of Stay, and Cost utilizing a National Electronic Health Record Database in 2020


Samuel Y Huang1
1 Icahn School of Medicine At Mount Sinai and Mount Sinai South Nassau, Oceanside, NY, United States of America


Abstract

Importance
Pulmonary artery catheters (PACs) play a pivotal role in managing acute hemodynamic decompensation, allowing for the assessment of right and left ventricular hemodynamic parameters and can allow for determination of SVO2 over echocardiogram. However, because of their invasive nature, increased understanding of their overall benefits is important. In certain populations with decrease compliance such as in patients with ischemia, information from PACs may be hard to utilize.

Aim
This study focuses on evaluating the impact of Pulmonary Artery Catheterizations (PAC) in patients with heart failure and ischemia admitted to the inpatient setting to discern whether PAC usage is associated with increased in hospital mortality rates, prolonged length of stay, costs, and complications. A subgroup analysis will be performed to see if there is a change in outcomes in individuals with and without cardiogenic shock as well as in individuals with mechanical circulatory support devices such as Intra-aortic balloon pumps (IABP), intraoperative Extracorporeal mechanical oxygenation (ECMO), mechanical ventilation, and renal dialysis. 

Objective
The utilization of pulmonary artery catheters (PACs) in guiding decision-making for the management of cardiogenic shock is a common practice. However, despite their widespread use, there is a paucity of robust evidence delineating the optimal application of PACs in the context of cardiogenic shock. The existing literature lacks conclusive support for the efficacy and benefits of obtaining hemodynamic data through early PAC placement in patients experiencing CS. This study seeks to address this gap by rigorously examining the association between early PAC placement and pertinent clinical outcomes, aiming to contribute evidence that can inform and optimize the management of cardiogenic shock.


Design, setting, and participants
This retrospective study utilized the National Inpatient Sample (NIS) data for the year 2020, focusing on patients with heart failure and diagnosis of ST elevation myocardial infarction (STEMI) with description of those experiencing cardiogenic shock, individuals receiving intra-aortic balloon pumps (IABPs), undergoing mechanical interventions, and those treated with extracorporeal membrane oxygenation (ECMO). Additionally, the study included patients who underwent Pulmonary Artery Catheterization (PAC).
Methods
ICD-10 codes lung cancers were identified from the American Medical Association Complete Official Handbook. Heart failure, Ischemia, and pulmonary artery catheterizationss ICD-10 codes. Multivariable linear regression and logistic regression models were employed, incorporating Charlson comorbidity, age, gender, race, and cardiogenic shock, to assess the impact of catheterization on length of stay, healthcare costs, and mortality in patients with heart failure, ischemia, and cardiogenic shock. Additionally, a Kaplan-Meier analysis was conducted to evaluate the time to 30-day discharge for patients who underwent catheterization, considering demographic variables and cardiogenic shock as potential influencing factors. 

Results
The final minimal dataset comprised a total of 114,647 individuals who had both congestive heart failure and ischemia, with a mean age of 70.66 years (SD = 13.37). Among these patients, 11.47% (13,147 individuals) experienced mortality. Females constituted 42.19% of the cohort. The mean length of hospital stay (LOS) for this population was 7.16 days (SD = 8.64). Notably, 5.52% of patients received pulmonary artery catheterization (PAC). Upon multivariable analysis pulmonary catheterization was associated with a 18% decreased mortality (95% CI: 0.76 – 0.89, pvalue < 0.001), increase length of stay of 2.1 days (95% CI 1.88 to 2.32, p<0.001), and increased cost of $20,150.37 (95% CI $19,109.28 to $21,191.46, pvalue < 0.001).

Conclusion
Using a nationally representative sample and a large dataset, pulmonary artery catheterizations in patients with congestive heart failure and a diagnosis of STEMI who received a PAC was associated with decreased mortality, increased length of stay and increased cost. Further studies are needed to characterize causation and to apply for each specific region and population of interest.

Association Between Pulmonary Artery Catheterization (PAC) Mortality, Length of Stay, and Cost utilizing a National Electronic Health Record Database in 2020

Background
Mobile low-dose computed tomography (LDCT) lung cancer screenings (LCS) are part of an outreach program in rural Appalachia to detect early malignancy in areas with limited healthcare access. While the primary goal is to screen for lung cancer, LDCT LCS can identify calcium deposits in coronary arteries and can prompt risk modification strategies for prevention of cardiovascular disease (CVD) events. There is no clear guidance for follow-up regarding CAC or prevention of associated CVD risk in patients undergoing LDCT LCS. The aim of this study was to determine how many patients with no known CVD had the presence of CAC on LDCT LCS. Secondary objectives were to determine if patients with CAC scores ≥100 received appropriate CVD risk reduction follow-up, and if initiation of statin or aspirin therapy occurred within 3 months after LDCT LCS. 

Methods
A retrospective review of mobile LDCT LCS from September 2021 to December 2022 was conducted in one large, tertiary health-system. Adult patients with no previous CVD history were included. CT images were obtained at 100 kVp with a slice thickness of 3 mm. Agatston CAC scoring was completed retroactively. Descriptive statistics and chi-square analyses were utilized.

Results
A total of 526 LDCT LCS were included. Over 54% of patients had coronary calcification on LDCT lung screening. 161 patients (30.6%) had a CAC score of ≥100 and 75 patients (14.3%) had a CAC score ≥400. Of patients with a CAC score ≥100, only 7.5% received referrals for follow-up and 9.3% had additional cardiac testing. Of those with a CAC score ≥100 not already on a statin (45.3%), only 8.2% were initiated on statin therapy within 3 months after LDCT LCS. Of those with a CAC score ≥100 not already on aspirin therapy (63.3%), only 5.9% were initiated on aspirin therapy within 3 months after LDCT LCS. Aspirin and statin initiations were dependent on calcium score (p<0.01).

Conclusion
In patients with no CVD history, CAC was frequently identified on mobile LDCT LCS in rural communities. Calcium scoring from LDCT lung screenings allowed for simultaneous assessment of lung cancer and CVD risk. Despite high CAC scores, there was limited initiation of cardiovascular disease prevention measures and follow-up, likely indicating missed opportunities for early intervention. Awareness of CAC score utility, follow-up for identified coronary calcification, and consideration of primary prevention medications when indicated, would be beneficial in patients undergoing LDCT lung cancer screenings, especially in rural areas with limited resources.

Premium content

Next from AMA Research Challenge 2024

Leveraging Machine Learning Models and Cytokines to Predict Vaccine Response: Exploring Demographic Influences

Similar lecture

Nicotine self-administration behavior under continuous versus intermittent access conditions in male and female rats

Stay up to date with the latest Underline news!

PRESENTATIONS

CONFERENCES

COMPANY

RESOURCES